These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 28067669)
1. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I. Brockhoff M; Rion N; Chojnowska K; Wiktorowicz T; Eickhorst C; Erne B; Frank S; Angelini C; Furling D; Rüegg MA; Sinnreich M; Castets P J Clin Invest; 2017 Feb; 127(2):549-563. PubMed ID: 28067669 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles. Ravel-Chapuis A; Al-Rewashdy A; Bélanger G; Jasmin BJ Hum Mol Genet; 2018 Oct; 27(19):3361-3376. PubMed ID: 29982462 [TBL] [Abstract][Full Text] [Related]
3. Antagonistic control of muscle cell size by AMPK and mTORC1. Mounier R; Lantier L; Leclerc J; Sotiropoulos A; Foretz M; Viollet B Cell Cycle; 2011 Aug; 10(16):2640-6. PubMed ID: 21799304 [TBL] [Abstract][Full Text] [Related]
4. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. Agarwal S; Bell CM; Rothbart SB; Moran RG J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients. Ravel-Chapuis A; Duchesne E; Jasmin BJ J Physiol; 2022 Jul; 600(14):3249-3264. PubMed ID: 35695045 [TBL] [Abstract][Full Text] [Related]
7. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice. Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581 [TBL] [Abstract][Full Text] [Related]
8. Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1. Timchenko L Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877772 [TBL] [Abstract][Full Text] [Related]
9. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. Huang H; Kang R; Wang J; Luo G; Yang W; Zhao Z Autophagy; 2013 Feb; 9(2):175-95. PubMed ID: 23169238 [TBL] [Abstract][Full Text] [Related]
11. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756 [TBL] [Abstract][Full Text] [Related]
12. Dysregulation of GSK3β-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients. Grande V; Hathazi D; O'Connor E; Marteau T; Schara-Schmidt U; Hentschel A; Gourdon G; Nikolenko N; Lochmüller H; Roos A J Neuromuscul Dis; 2021; 8(4):603-619. PubMed ID: 33682722 [TBL] [Abstract][Full Text] [Related]
13. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development. Michel L; Huguet-Lachon A; Gourdon G PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785 [TBL] [Abstract][Full Text] [Related]
14. Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner. Misquitta NS; Ravel-Chapuis A; Jasmin BJ Hum Mol Genet; 2023 Jan; 32(4):551-566. PubMed ID: 36048859 [TBL] [Abstract][Full Text] [Related]
15. Capsaicin induces apoptosis in human osteosarcoma cells through AMPK-dependent and AMPK-independent signaling pathways. Ying H; Wang Z; Zhang Y; Yang TY; Ding ZH; Liu SY; Shao J; Liu Y; Fan XB Mol Cell Biochem; 2013 Dec; 384(1-2):229-37. PubMed ID: 24005536 [TBL] [Abstract][Full Text] [Related]
16. AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response. Li H; Min Q; Ouyang C; Lee J; He C; Zou MH; Xie Z Biochim Biophys Acta; 2014 Sep; 1842(9):1844-54. PubMed ID: 25016145 [TBL] [Abstract][Full Text] [Related]
17. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells. Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047 [TBL] [Abstract][Full Text] [Related]
18. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Orengo JP; Chambon P; Metzger D; Mosier DR; Snipes GJ; Cooper TA Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2646-51. PubMed ID: 18272483 [TBL] [Abstract][Full Text] [Related]
19. AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1. Sanchez AM; Csibi A; Raibon A; Cornille K; Gay S; Bernardi H; Candau R J Cell Biochem; 2012 Feb; 113(2):695-710. PubMed ID: 22006269 [TBL] [Abstract][Full Text] [Related]
20. Mechanical stretch activates mammalian target of rapamycin and AMP-activated protein kinase pathways in skeletal muscle cells. Nakai N; Kawano F; Nakata K Mol Cell Biochem; 2015 Aug; 406(1-2):285-92. PubMed ID: 25971373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]